Highest-materiality recent filing
SeaStar Medical Q1 revenue $0.5M, up 69% YoY; net loss $3.5M
Net revenue of $0.5M from QUELIMMUNE sales, vs $0.3M in Q1 2025.
SeaStar Medical's securities class action lawsuit dismissed with prejudice
Class action filed July 5, 2024, alleged material misstatements culminating in March 2024 restatement.
SeaStar Medical Q4 2025 revenue $420K; net loss narrows to $2.9M; cash grows to $12M
Net revenue Q4 2025 $420K (vs $67K Q4 2024); full year $1.2M (vs $135K).
SeaStar Medical moves reverse stock split effective date to Jan 5, 2026
1-for-10 reverse stock split effective 12:01 AM ET on January 5, 2026.
SeaStar Medical shareholders approve 1-for-10 reverse stock split effective Jan 2, 2026
Reverse split approved with 16.5M for, 5.6M against; authorized shares cut by 25M to 425M.
SeaStar Medical Q3 revenue $0.2M, net loss $3.5M; QUELIMMUNE orders rising
Net revenue $0.2M (Q3 2024: $0.1M); net loss $3.5M ($0.13/sh) vs $4.5M ($1.10/sh) a year ago.
SeaStar Medical DSMB recommends continue NEUTRALIZE-AKI trial; enrollment target raised to 339
DSMB reports zero device-related safety issues in first 100 patients; recommends continuation of pivotal AKI trial.
SeaStar Medical terminates CFO David Green, appoints CEO Eric Schlorff as interim CFO
David Green terminated as CFO and Treasurer effective Aug 14, 2025; termination without cause.
SeaStar Medical Q2 net loss $2.0M on $0.3M revenue; NEUTRALIZE-AKI trial 60% enrolled
Net loss of $2.0M ($0.18/share) vs $3.2M ($1.03/share) in Q2 2024; revenue from QUELIMMUNE pediatric SCD was $0.3M.
SeaStar Medical Q2 net loss $2.0M; NEUTRALIZE-AKI trial over 60% enrolled
Net revenue $0.3M from QUELIMMUNE sales; net loss $2.0M ($0.18/share) vs $3.2M loss year ago.
SeaStar Medical receives Nasdaq deficiency notice for bid price below $1.00
Deficiency letter received July 31, 2025; closing bid price below $1.00 for 30 consecutive business days.
SeaStar Medical receives Nasdaq bid price deficiency notice; 180-day cure period until Jan 27, 2026
Nasdaq notified SeaStar that common stock (ICU) closing bid price below $1.00 for 30 consecutive trading days.
SeaStar Medical raises $4.4M in registered direct offering and private placement of warrants
Sold 4,960,544 shares at $0.887 per share, plus unregistered warrants for same number at $0.762.
SeaStar Medical raises ~$4M in registered direct offering plus warrants at $0.763/share
Registered direct offering of 5,242,464 shares (or equivalents) at $0.763 per share, plus unregistered warrants for equal number at $0.638.
SeaStar Medical regains Nasdaq equity compliance; needs funds by end of July
Confirmed compliance with Nasdaq's $2.5M minimum stockholders' equity requirement; listing matter closed.
SeaStar Medical raises $4M in public offering, cuts executive salaries by 20%
SeaStar Medical priced a public offering of 6,153,847 shares, pre-funded warrants, and Series A/B warrants at $0.65 per combined unit, expecting approximately $4M gross proceeds.
SeaStar Medical Q1 net revenue rises to $293K; net loss narrows to $3.8M
Net product revenue ~$293K, a four-fold increase from Q4 2024's $68K.
SeaStar Medical in $15M equity line with Lincoln Park Capital Fund
Lincoln Park committed to buy up to $15M of common stock over 36-month period.
SeaStar Medical reports FY2024 net loss $24.8M; first product revenue $0.1M from QUELIMMUNE launch
Net loss for 2024 was $24.8M ($6.63 per share) vs $26.2M ($30.26) in 2023.
Nasdaq panel grants SeaStar Medical continued listing exception until June 22, 2025
Nasdaq Hearings Panel granted continued listing subject to compliance with Nasdaq Listing Rule 5550(b)(2) (MVLS Rule) requiring $35M market value by June 22, 2025.
SeaStar Medical reports 5,997,246 shares outstanding; updates on clinical and commercial progress
As of Dec 31, 2024, common shares outstanding: 5,997,246 (Jan 8, 2025: 5,977,246).
SeaStar Medical receives Nasdaq delisting notice for failing minimum market value rule
Nasdaq notified SeaStar on Dec 24, 2024 that it failed to regain compliance with $35M minimum market value of listed securities.
SeaStar Medical faces derivative lawsuit over alleged false FDA approval statements
Filed Dec 13, 2024 in US District Court for Colorado by shareholder Jose Lazo.
First commercial revenue of $67,500 from direct QUELIMMUNE shipments to hospital customer; no revenue in Q3 2023.
SeaStar Medical enters $25M ATM equity facility with H.C. Wainwright
ATM agreement allows sale of up to $25M in common stock via at-the-market offerings on Nasdaq.
SeaStar Medical Q2 net loss $3.2M; first commercial QUELIMMUNE sales in July
Net loss $3.2M ($1.03/share) vs $2.4M ($4.10/share) in Q2 2023, driven by higher R&D and G&A.
SeaStar Medical raises $10M via registered direct offering and warrants
Issued 947,868 shares at $10.55 each, raising ~$10M gross proceeds.
Plaintiff Forrest A K Wells filed putative class action on July 5, 2024 in Colorado federal court.
SeaStar Medical self-reports potential Nasdaq rule violation for share issuance
Company notified Nasdaq of possible violation of Listing Rule 5635(d)(2) regarding convertible-note conversion and warrant exercise.
SeaStar Medical receives Nasdaq MVLS deficiency notice; regains bid price compliance
On June 24, 2024, SeaStar received Nasdaq deficiency letter for MVLS below $35M minimum for 35 consecutive days.
SeaStar Medical Q1 net loss $12.7M, cash rises to $5M; Quelimmune launch imminent
Net loss $12.7M ($0.19 per share) vs $7.1M ($0.54) in Q1 2023; no revenue recorded.
the Company issued a press release announcing the appointment of John Neuman and the two newly elected members to the Board, Ms. Jennifer A. Baird, and Ms. Bernadette N. Vincent.
the Company issued a press release announcing the appointment of John Neuman and the two newly elected members to the Board, Ms. Jennifer A. Baird, and Ms. Bernadette N. Vincent.
the Board of Directors (the Board") of SeaStar Medical Holding Corporation (the "Company") appointed Mr. John Neuman as a Class I director, effective immediately
Mr. Andres Lobo informed the Board that he will resign as a director of the Company, effective as of June 5, 2024.
Max materiality 0.85 · Median 0.60 · Most common event other_material